Evidence map›Paper›PMID 40666361›Full record

ArticlemedRxiv : the preprint server for health sciences2025

Cell-type-resolved genetic regulatory variation shapes inflammatory bowel disease risk.

Tobi Alegbe, Bradley T Harris, Laura Fachal, Lucia Ramirez-Navarro, Marcus Tutert, Monika Krzak, Mennatallah Ghouraba, Michelle Strickland, Matiss Ozols, Saniya Khoullar and 23 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Tobi AlegbeWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0003-1622-0502
Bradley T HarrisWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0001-9585-1016
Laura FachalWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0002-7256-9752
Lucia Ramirez-NavarroWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0003-2194-2438
Marcus TutertWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0002-4177-3371
Monika KrzakWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0009-0005-4157-7126
Mennatallah GhourabaWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0003-4671-3500
Michelle StricklandWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0001-8053-400X
Matiss OzolsWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0001-5663-1053
Saniya KhoullarWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0002-4166-874X
Eleonora KhabirovaWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0002-5891-6789
Nikolaos I PanousisGlaxoSmithKline, Gunnels Wood Road, Stevenage, UK.ORCID 0000-0003-2890-5592
David OchoaOpen Targets, Hinxton, CB10 1SA, UK.ORCID 0000-0003-1857-278X
Noor WanaWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0009-0006-6982-1474
May Xueqi HuWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0009-0003-2727-8141
Jason SkeltonWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Jasmin OstermayerWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0001-6461-398X
Kimberley Ai Xian CheamWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
D Leland TaylorWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0001-6498-6970
Yong GuWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Claire DawsonAddenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Tina ThompsonAddenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Kenneth ArestangAddenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Nilanga NishadAddenbrooke's Hospital, Cambridge CB2 0QQ, UK.ORCID 0000-0002-3143-4181
Steven LeonardWellcome Sanger Institute, Hinxton, CB10 1SA, UK.
Vivek IyerWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0002-7536-0954
Rebecca E McIntyreWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0001-5291-1533
Miles ParkesAddenbrooke's Hospital, Cambridge CB2 0QQ, UK.ORCID 0000-0002-6467-0631
Chris WallaceDepartment of Medicine, University of Cambridge, Cambridge, CB2 0QQ, UK.ORCID 0000-0001-9755-1703
Cristina Cotobal MartinWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0002-5877-2228
Gareth-Rhys JonesUniversity of Edinburgh Centre for Inflammation Research, Queens Medical Research institute, Edinburgh EH16 4TJ, UK.ORCID 0000-0001-7355-2357
Tim RaineOpen Targets, Hinxton, CB10 1SA, UK.ORCID 0000-0002-5855-9873
Carl A AndersonWellcome Sanger Institute, Hinxton, CB10 1SA, UK.ORCID 0000-0003-1719-7009

Funding

Wellcome Trust
6 · The paper itself

Abstract

Most genetic variants associated with complex diseases lie in non-coding regions, complicating efforts to identify effector genes and relevant cell types. Here, we map cis-eQTLs across 2.2 million single cells from blood and intestinal biopsies of 421 individuals, including 125 with inflammatory bowel disease (IBD). Cell-type-level eQTLs were more distal to transcription start sites, enriched in enhancers, less likely to regulate the nearest gene, and over two-fold more likely to colocalise with IBD GWAS loci than eQTLs detected at tissue-level resolution. We nominate effector genes at over half of known IBD loci, including

Identifiers

PMID40666361
PMCPMC12262763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.